TY - JOUR
T1 - Behavioral defects in a DCTN1G71A transgenic mouse model of Perry syndrome
AU - Mishima, Takayasu
AU - Deshimaru, Manami
AU - Watanabe, Takuya
AU - Kubota, Kaori
AU - Kinoshita-Kawada, Mariko
AU - Yuasa-Kawada, Junichi
AU - Takasaki, Kotaro
AU - Uehara, Yoshinari
AU - Jinno, Shozo
AU - Iwasaki, Katsunori
AU - Tsuboi, Yoshio
N1 - Funding Information:
We thank members of the Tsuboi, Iwasaki, Jinno, and Kang laboratories for fruitful discussions. This work was supported by JSPS KAKENHI (grant number 26860678 to TM).
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/2/14
Y1 - 2018/2/14
N2 - Perry syndrome is a rare neurodegenerative disease characterized by parkinsonism, depression/apathy, weight loss, and central hypoventilation. Our previously-conducted genome-wide association scan and subsequent studies identified nine mutations in DCTN1, the largest protein subunit of the dynactin complex, in patients with Perry syndrome. These included G71A in the microtubule-binding cytoskeleton-associated protein Gly-rich domain of p150Glued. The dynactin complex is essential for function of the microtubule-based cytoplasmic retrograde motor dynein. To test the hypothesis that the G71A mutation in the DCTN1 gene is sufficient to cause Perry syndrome, we generated DCTN1G71A transgenic mice. These mice initially developed normally, but young animals showed decreased exploratory activity and aged animals showed impaired motor coordination. These behavioral defects parallel apathy-like symptoms and parkinsonism encountered in Perry syndrome. TDP-43 aggregates were not detected in the substantia nigra and cerebral cortex of the transgenic mice, although pathological aggregates of TDP-43 have been considered a major neuropathological feature of Perry syndrome. Our study reveals that a single mutation in the DCTN1 gene recapitulates symptoms of Perry syndrome patients, and provides evidence that DCTN1G71A transgenic mice represent a novel rodent model of Perry syndrome.
AB - Perry syndrome is a rare neurodegenerative disease characterized by parkinsonism, depression/apathy, weight loss, and central hypoventilation. Our previously-conducted genome-wide association scan and subsequent studies identified nine mutations in DCTN1, the largest protein subunit of the dynactin complex, in patients with Perry syndrome. These included G71A in the microtubule-binding cytoskeleton-associated protein Gly-rich domain of p150Glued. The dynactin complex is essential for function of the microtubule-based cytoplasmic retrograde motor dynein. To test the hypothesis that the G71A mutation in the DCTN1 gene is sufficient to cause Perry syndrome, we generated DCTN1G71A transgenic mice. These mice initially developed normally, but young animals showed decreased exploratory activity and aged animals showed impaired motor coordination. These behavioral defects parallel apathy-like symptoms and parkinsonism encountered in Perry syndrome. TDP-43 aggregates were not detected in the substantia nigra and cerebral cortex of the transgenic mice, although pathological aggregates of TDP-43 have been considered a major neuropathological feature of Perry syndrome. Our study reveals that a single mutation in the DCTN1 gene recapitulates symptoms of Perry syndrome patients, and provides evidence that DCTN1G71A transgenic mice represent a novel rodent model of Perry syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85038954557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038954557&partnerID=8YFLogxK
U2 - 10.1016/j.neulet.2017.12.038
DO - 10.1016/j.neulet.2017.12.038
M3 - Article
C2 - 29273399
AN - SCOPUS:85038954557
SN - 0304-3940
VL - 666
SP - 98
EP - 103
JO - Neuroscience Letters
JF - Neuroscience Letters
ER -